Monte Rosa Therapeutics Financials - Benzinga

SPY765.54+0.38%QQQ742.80+0.41%BTC/USD83,473.18−0.10%DIA510.23+0.33%GLD381.00+0.04%TLT77.77−0.01%

Monte Rosa Therapeutics Inc

GLUENASDAQ

Trade with Public

Trade with Public

$11.93

0.191.62%

At close: Sep 30, 5:00 PM EST

$13.90

1.9716.51%

After Hours: 7:57 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Monte Rosa Therapeutics Financials

Monte Rosa Therapeutics (GLUE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over losses of $(0.15) per

Benzinga Newsdesk

PRO
Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 178.95 percent decrease over earnings of $0.57 per

Benzinga Newsdesk

PRO
Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.33) by 65.17 percent. This is a 339.13 percent decrease over earnings of $0.23 per

Benzinga Newsdesk

Crude Oil Down 2%; ISM Services PMI Surges In December

Avi Kapoor

PRO
Monte Rosa Therapeutics Q3 EPS $(0.33) Beats $(0.37) Estimate, Sales $12.768M Beat $5.420M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.37) by 11.53 percent. This is a 13.79 percent decrease over losses of $(0.29) per

Benzinga Newsdesk

PRO
Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate

Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly sales of $12.768 million which beat the analyst consensus estimate of $5.420 million by 135.57 percent. This is a 38.54 percent increase over sales of $9.216

Benzinga Newsdesk